| 2026-09-03 | 8-K | Form 8-K, Item 7.01 |
| 2026-08-14 | Deck | Climb Bio Investor Presentation August 2026 |
| 2026-08-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-06 | Press release | Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-01 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-12 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-11 | Press release | Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocyto |
| 2026-06-11 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-08 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-05 | Press release | Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association |
| 2026-06-05 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-26 | Press release | Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 |
| 2026-05-14 | Press release | Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress |
| 2026-05-12 | Press release | Climb Bio to Present at Upcoming Investor Conferences |
| 2026-05-07 | Press release | Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Deck | Budoprutug and the CD19 Opportunity |
| 2026-05-05 | Press release | Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Medi |
| 2026-05-05 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-28 | Press release | Climb Bio, Inc. Announces $110.0 Million Private Placement |
| 2026-04-28 | 8-K | Form 8-K, Item 1.01 |
| 2026-04-24 | Proxy | Definitive proxy statement |
| 2026-04-08 | Press release | Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 |
| 2026-04-03 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-05 | Press release | Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates |
| 2026-03-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-01-08 | 8-K | Form 8-K, Item 7.01 |
| 2025-12-31 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-11 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-06 | Press release | Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 2025-11-06 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-06 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-17 | 8-K | Form 8-K, Item 8.01 |
| 2025-10-01 | 8-K | Form 8-K, Item 5.02 |
| 2025-09-29 | Deck | CLYM116 and the IgA Nephropathy (IgAN) Opportunity |
| 2025-09-29 | 8-K | Form 8-K, Item 7.01 |